Determination of serum total lipid and free N-acetylneuraminic acid in genitourinary malignancies by fluorimetric high performance liquid chromatography. Relevance of free N-acetylneuraminic acid as tumour marker

Abstract

The reliability of total sialic acid (TSA), lipid sialic acid (LSA) and free sialic acid (FSA) as markers in genitourinary malignancies was evaluated in 20 normal subjects, 21 patients with prostatic cancer, 22 patients with urinary bladder cancer and 14 patients with renal cell carcinoma. We introduce the new concept of ‘corrected’ lipid sialic acid (CLSA), which expresses the actual concentration of sialic acid bound to glycolipids by subtracting the concentration of FSA determined by a novel ultrafiltration method. TSA did not show significant differences with respect to normal controls, except for renal cell carcinoma, whose mean value (879 ± 145 μg/ml) showed a P value < 0.001. Instead, CLSA showed only significant differences ( P = 0.001), with respect to normal controls in stage I and in all grades of renal cell carcinoma. While all data indicated significant increases ( P = 0.001) in the FSA values, (means ± S.D.) of 0.621 ± 0.272 μg/ml were found in patients with prostatic cancer, 0.796 ± 0.443 μg/ml in patients with urinary bladder cancer and 0.667 ± 0.146 μg/ml in patients with renal cell carcinoma. Separate TSA and CLSA measurements appeared to be of limited value in the detection of genitourinary malignancies. However, results show that FSA was the most sensitive of the three markers tested for detecting malignancies.